Citation Report
List of articles citing

Ifosfamide clinical pharmacokinetics

DOI: 10.2165/00003088-199426060-00003
Clinical Pharmacokinetics, 1994, 26, 439-56.

#	Paper	IF	Citations
71	The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. *British Journal of Clinical Pharmacology*, **1995**, 40, 523-30	3.8	224
70	Trace analysis of the antineoplastics ifosfamide and cyclophosphamide in sewage water by twostep solid-phase extraction and gas chromatography-mass spectrometry. *Journal of Chromatography A*, **1996**, 726, 179-184	4.5	133
69	Overview of recent topics in clinical pharmacology of anticancer agents. *Cancer Chemotherapy and Pharmacology*, **1998**, 42 Suppl, S22-30	3.5	28
68	The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study. *British Journal of Cancer*, **1998**, 77, 978-84	8.7	22
67	Effects of a combined thermochemotherapy on the xenotransplanted human mammary carcinoma MX-1. A light and transmission electron microscopic study. *Annals of Anatomy*, **1998**, 180, 253-60	2.9	1
66	Practical treatment guide for dose individualisation in cancer chemotherapy. *Drugs*, **1998**, 56, 1019-38	12.1	68
65	Pharmacological and histopathological study of cyclophosphamide-induced hemorrhagic cystitis - comparison of the effects of dexamethasone and Mesna. *Brazilian Journal of Medical and Biological Research*, **1999**, 32, 1211-5	2.8	29
64	Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. *In Vitro Cellular and Developmental Biology - Animal*, **1999**, 35, 314-7	2.6	34
63	Enantioselective induction of cyclophosphamide metabolism by phenytoin. *Chirality*, **1999**, 11, 569-74	2.1	28
62	Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions. *Journal of Medicinal Chemistry*, **1999**, 42, 2542-60	8.3	48
61	Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. *Chest*, **2000**, 118, 1208-10	5.3	21
60	The clinical pharmacology of alkylating agents in high-dose chemotherapy. *Anti-Cancer Drugs*, **2000**, 11, 515-33	2.4	35
59	Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. *British Journal of Clinical Pharmacology*, **2000**, 50, 315-24	3.8	31
58	Manic episode in an ifosfamide-treated patient. *General Hospital Psychiatry*, **2000**, 22, 52-3	5.6	7
57	Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. *Journal of Clinical Oncology*, **2000**, 18, 2576-81	2.2	11
56	Stereoselective pharmacokinetics of ifosfamide in male and female rats. *AAPS PharmSci*, **2000**, 2, E17		4
55	Metabolism and pharmacokinetics of oxazaphosphorines. *Clinical Pharmacokinetics*, **2000**, 38, 291-304	6.2	156

54	Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. *Clinical Pharmacokinetics*, **2001**, 40, 41-62	6.2	79
53	Ifosfamide encephalopathy presenting with asterixis. *Journal of the Neurological Sciences*, **2002**, 199, 85-8	3.2	21
52	Ifosfamide impairs the allostimulatory capacity of human dendritic cells by intracellular glutathione depletion. *Blood*, **2003**, 102, 3668-74	2.2	39
51	Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. *Advances in Cancer Research*, **2004**, 91, 69-136	5.9	175
50	Disturbed Ca2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity. *Kidney International*, **2005**, 68, 2029-41	9.9	25
49	Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. *Pediatric Nephrology*, **2005**, 20, 872-85	3.2	64
48	Ifosfamide Encephalopathy: A Case Report. *Tumori*, **2005**, 91, 197-200	1.7	4
47	Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. *Annals of Oncology*, **2005**, 16, 1974-8	10.3	20
46	Metabolism and transport of oxazaphosphorines and the clinical implications. *Drug Metabolism Reviews*, **2005**, 37, 611-703	7	137
45	Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. *Cancer Chemotherapy and Pharmacology*, **2006**, 57, 349-56	3.5	20
44	Enantioselective metabolism of ifosfamide by the kidney. *Chirality*, **2006**, 18, 398-405	2.1	4
43	Ifosfamide-induced nephrotoxicity: mechanism and prevention. *Cancer Research*, **2006**, 66, 7824-31	10.1	57
42	[14C]bis(2-chloroethoxy)methane: comparative absorption, distribution, metabolism and excretion in rats and mice. *Xenobiotica*, **2007**, 37, 427-40	2	4
41	Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. *Anti-Cancer Drugs*, **2007**, 18, 543-53	2.4	6
40	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. *European Journal of Cancer*, **2007**, 43, 14-34	7.5	198
39	Ifosfamide induces acute renal failure via inhibition of the thioredoxin reductase activity. *Free Radical Biology and Medicine*, **2007**, 43, 1574-83	7.8	17
38	Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. *Toxicology and Applied Pharmacology*, **2007**, 222, 33-41	4.6	35
37	Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells. *Pediatric Nephrology*, **2007**, 22, 798-803	3.2	12

36	Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: the impact of oxidative stress. *Pediatric Blood and Cancer*, **2008**, 51, 613-5	3	27
35	Differential effects of ifosfamide on dendritic cell-mediated stimulation of T cell interleukin-2 production, natural killer cell cytotoxicity and interferon-gamma production. *Clinical and Experimental Immunology*, **2008**, 153, 429-38	6.2	5
34	Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. *European Journal of Pharmacology*, **2008**, 579, 66-73	5.3	28
33	Urological implications of cyclophosphamide and ifosfamide. *Scandinavian Journal of Urology and Nephrology*, **2008**, 42, 309-17		40
32	Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. *Cancer Control*, **2008**, 15, 38-46	2.2	52
31	Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis. *Sarcoma*, **2009**, 2009, 575629	3.1	7
30	Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. *European Journal of Haematology*, **1999**, 62, 223-30	3.8	16
29	Detection and quantification of (R) and (S)-dechloroethylifosfamide metabolites in plasma from children by enantioselective LC/MS/MS. *Chirality*, **2009**, 21, 674-80	2.1	12
28	Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7. *Journal of Applied Toxicology*, **2010**, 30, 204-11	4.1	4
27	Vasorelaxation Effects of 2-Chloroethanol and Chloroacetaldehyde in the Isolated Rat Aortic Rings. *Journal of Health Science*, **2009**, 55, 525-531		4
26	Targets of chloroacetaldehyde-induced nephrotoxicity. *Toxicology in Vitro*, **2010**, 24, 99-107	3.6	16
25	Effects of chloroacetaldehyde in 2-chloroethanol-induced cardiotoxicity. *Food and Chemical Toxicology*, **2011**, 49, 1063-7	4.7	6
24	The effect of N-acetylcysteine on the antitumor activity of ifosfamide. *Canadian Journal of Physiology and Pharmacology*, **2011**, 89, 335-43	2.4	5
23	Use of precision-cut renal cortical slices in nephrotoxicity studies. *Xenobiotica*, **2013**, 43, 54-62	2	10
22	Oral delivery of anticancer drugs: challenges and opportunities. *Journal of Controlled Release*, **2013**, 170, 15-40	11.7	329
21	A New Method to Quantify Ifosfamide Blood Levels Using Dried Blood Spots and UPLC-MS/MS in Paediatric Patients with Embryonic Solid Tumours. *PLoS ONE*, **2015**, 10, e0143421	3.7	10
20	Selected organophosphorus compounds with biological activity. Applications in medicine. *RSC Advances*, **2016**, 6, 7101-7112	3.7	117
19	Development of Tumor-Specific Caffeine-Potentiated Chemotherapy Using Span 80 Nano-Vesicles DDS. **2017**,		

18	Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis. *Oncotarget*, **2017**, 8, 49515-49533	3.3	7
17	Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis. *Journal of Cellular Biochemistry*, **2018**, 119, 250-259	4.7	4
16	The Ameliorating Effect of Plasma Protein from on Cyclophosphamide-Induced Acute Kidney Injury in Mice. *Marine Drugs*, **2019**, 17,	6	15
15	Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. *Annals of Hematology*, **2020**, 99, 2577-2586	3	
14	Protective Effect of Low Molecular Weight Peptides from Head against Cyclophosphamide-Induced Nephrotoxicity in Mice the Keap1/Nrf2 Pathway. *Antioxidants*, **2020**, 9,	7.1	5
13	A bioimaging system combining human cultured reporter cells and planar chromatography to identify novel bioactive molecules. *Analytica Chimica Acta*, **2021**, 1183, 338956	6.6	5
12	Pharmacological considerations of primary alkylators. *Cancer Treatment and Research*, **2002**, 112, 323-45	3.5	4
11	Phosphoramide and Oxazaphosphorine Mustards. **1997**, 23-79		5
10	Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2000**, 23, 358-63	2.7	18
9	Metabolic Models of Cytotoxicity. **1999**, 443-476		1
8	Incorporating ifosfamide into salvia oil-based nanoemulsion diminishes its nephrotoxicity in mice inoculated with tumor. *BioImpacts*, **2020**, 10, 9-16	3.5	4
7	Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 1615-1623	12.7	67
6	Malignes Wachstum. **2005**, 425-465		
5	Niereninsuffizienz, Nierenversagen. **2006**, 753-756		
4	A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature.. *BMC Pediatrics*, **2022**, 22, 76	2.6	1
3	İfosfamid ve Kurkumin Kombinasyonun Küçük Hücreli Dışı Akciğer Kanseri Hücresinde Apoptotik Biyobelirteçler ve Hücre Gelişerine Etkileri. *Türk Doğa Ve Fen Dergisi*, **2021**, 10, 295-302	0	
2	Mitochondrial Transplantation Therapy against Ifosfamide Induced Toxicity on Rat Renal Proximal Tubular Cells.		1
1	Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective. **2023**, 15, 1283		0